{"id":"W4391303701","doi":"10.1200/jco.2024.42.4_suppl.165","title":"Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Prostate cancer; Abiraterone; Homologous recombination; PARP inhibitor; Internal medicine; Oncology; Enzalutamide; Placebo; Cancer research; Gene; Urology; Cancer; Poly ADP ribose polymerase; Androgen receptor; Genetics; Pathology; Polymerase; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00108797,0.0007842463,0.001196338,0.0003361152,0.0001820261,0.0008340887,0.0004642033,0.0006264914,0.002650124],"category_scores_gemma":[0.001131566,0.0002713964,0.001018742,0.0003278058,0.0005562315,0.0006479344,0.0003073716,0.001616285,0.000387776],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004357817,"about_ca_system_score_gemma":0.0006980537,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003452769,"about_ca_topic_score_gemma":0.001016655,"domain_scores_codex":[0.9996982,0.0001771793,0.0000181783,0.00004072207,0.00002361231,0.00004219357],"domain_scores_gemma":[0.999421,0.0001937138,0.0001415623,0.00002521205,0.00002182485,0.0001967617],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.948881,0.003443001,0.001141874,0.0005926579,0.0007070868,0.00006099361,0.00004762553,0.0007752672,0.004483081,0.0001061686,0.000648472,0.03911272],"study_design_scores_gemma":[0.6941787,0.2930119,0.006512401,0.000102161,0.001063962,0.0001777653,0.00005758005,0.001096298,0.001561029,0.0004269092,0.00178366,0.00002764252],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889855,0.006871144,0.0003547558,0.0004234613,0.0002032194,0.0007206122,0.0006351919,0.00006454627,0.001741468],"genre_scores_gemma":[0.9951959,0.00188471,0.0005279515,0.0003492251,0.0001607785,0.0005290081,0.0005012768,0.000008666119,0.0008425518],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002650124,"threshold_uncertainty_score":0.008865535,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1479448430826232,"score_gpt":0.4479502338116599,"score_spread":0.3000053907290367,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}